Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients

BACKGROUND: Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation. Cytomegalovirus genotyping was performed to identi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: Douglas, Cameron M, Barnard, Richard, Holder, Daniel, Leavitt, Randi, Levitan, Diane, Maguire, Maureen, Nickle, David, Teal, Valerie, Wan, Hong, van Alewijk, Dirk C J G, van Doorn, Leen-Jan, Chou, Sunwen, Strizki, Julie
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Major Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7075417/
https://ncbi.nlm.nih.gov/pubmed/31781762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiz577
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados